Glaucoma and generics in Europe

A. Hommer
{"title":"Glaucoma and generics in Europe","authors":"A. Hommer","doi":"10.24292/01.OT.300319.05","DOIUrl":null,"url":null,"abstract":"Original drugs and generic drugs used in glaucoma differ from each other. This can lead to worse drug tolerability and, as a result, to worse patients’ compliance. Therefore, an essential issue is, besides the drug’s efficacy, its optimal tolerability for the patient. The potential differences in viscosity, pH, drop size, and surface tension has a potential strong influence on the complex delivery mechanism of the active molecule to the receptors in the eye and its clinical relevant efficacy. These differences, in addition to different appearance and handling of a “new” bottle, may pose problems with patients’ compliance after using a new preparation.","PeriodicalId":112284,"journal":{"name":"OphthaTherapy. Therapies in Ophthalmology","volume":"42 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OphthaTherapy. Therapies in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24292/01.OT.300319.05","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Original drugs and generic drugs used in glaucoma differ from each other. This can lead to worse drug tolerability and, as a result, to worse patients’ compliance. Therefore, an essential issue is, besides the drug’s efficacy, its optimal tolerability for the patient. The potential differences in viscosity, pH, drop size, and surface tension has a potential strong influence on the complex delivery mechanism of the active molecule to the receptors in the eye and its clinical relevant efficacy. These differences, in addition to different appearance and handling of a “new” bottle, may pose problems with patients’ compliance after using a new preparation.
欧洲的青光眼和仿制药
治疗青光眼的原研药和仿制药各不相同。这可能导致更差的药物耐受性,从而导致更差的患者依从性。因此,一个重要的问题是,除了药物的疗效,它对病人的最佳耐受性。黏度、pH值、液滴大小和表面张力的潜在差异对活性分子向眼内受体的复杂递送机制及其临床相关疗效有潜在的强烈影响。这些差异,加上“新”瓶的外观和处理方式的不同,可能会给患者使用新制剂后的依从性带来问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信